Clinical Trial Update: Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan

View source ↗

Summary

A completed clinical trial assessed beta cell mass in type 1 diabetes using the radiotracer 11C-dihydrotetrabenazine with PET imaging.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• 11C-Dihydrotetrabenazine (11C-dihydrotetrabenazine)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Type I Diabetes | Status: COMPLETED